Halozyme Therapeutics (HALO) PT Raised to $79 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
TD Cowen analyst Brendan Smith raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $79.00 (from $77.00) while maintaining a Buy rating.
The analyst comments: "Top/bottom line beat/raise in Q1 is near best-case scenario for HALO made even more impressive given broader biopharma headwinds. Strong royalties from Darzalex/Phesgo strength & Vyvgart Hytrulo's outperformance + raised FY25 guidance support new PT of $79 (+$2). We still see additional upside potential from ongoing launches, buybacks + MRK litigation, all of which reaffirm HALO as a top pick."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oil States International (OIS) PT Lowered to $11 at Raymond James
- These 3 EU chip stocks screen as most de-risked sector bets: UBS
- Citi reiterates neutral rating on Okta amid data leak concerns
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cowen & Co, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
